13F HOLDINGS REPORT
Sanofi
Quarter ended Q4 2025 · Filed February 11, 2026 · Accession 0001193125-26-045633
Total Value
$310.4M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | MGTX | 12,197,737 | $97.0M | 31.24% |
| 2 | Inhibrx Biosciences, Inc. | INBX | 1,157,926 | $91.5M | 29.47% |
| 3 | Novavax | NVAX | 6,880,481 | $46.2M | 14.90% |
| 4 | AnaptysBio | ANABV | 821,917 | $39.8M | 12.84% |
| 5 | Immuneering Corp | IMRX | 2,708,559 | $17.8M | 5.74% |
| 6 | MapLight Therapeutics Inc. | MPLT | 912,041 | $16.0M | 5.16% |
| 7 | Eledon | ELDN | 814,980 | $1.2M | 0.40% |
| 8 | Q32 Bio Inc. | QTTB | 244,083 | $810,356 | 0.26% |